• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚太肝脏研究学会关于丙型肝炎预防、流行病学及实验室检测的共识声明与建议

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

作者信息

Omata Masao, Kanda Tatsuo, Wei Lai, Yu Ming-Lung, Chuang Wang-Long, Ibrahim Alaaeldin, Lesmana Cosmas Rinaldi Adithya, Sollano Jose, Kumar Manoj, Jindal Ankur, Sharma Barjesh Chander, Hamid Saeed S, Dokmeci A Kadir, Al-Mahtab Mamun, McCaughan Geofferey W, Wasim Jafri, Crawford Darrell H G, Kao Jia-Horng, Yokosuka Osamu, Lau George K K, Sarin Shiv Kumar

机构信息

Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan.

The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

出版信息

Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.

DOI:10.1007/s12072-016-9736-3
PMID:27229718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5003900/
Abstract

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

摘要

亚太肝脏研究协会(APASL)于2015年3月召集了一个关于“APASL丙型肝炎管理共识声明和建议”的国际工作小组,以修订“丙型肝炎病毒感染的APASL共识声明和管理算法”(《肝病国际》6:409 - 435,2012年)。该工作小组由来自亚太地区的肝病专家组成,于2015年3月13日聚集在土耳其伊斯坦布尔的伊斯坦布尔会议中心。在起草修订稿的过程中,展示、讨论并辩论了新的数据。共识会议的参与者评估了所引用研究的质量。本综述给出了关于丙型肝炎预防、流行病学和实验室检测的最终建议。

相似文献

1
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.亚太肝脏研究学会关于丙型肝炎预防、流行病学及实验室检测的共识声明与建议
Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.
2
APASL consensus statements and recommendation on treatment of hepatitis C.亚太肝脏研究学会关于丙型肝炎治疗的共识声明与建议
Hepatol Int. 2016 Sep;10(5):702-26. doi: 10.1007/s12072-016-9717-6. Epub 2016 Apr 29.
3
APASL consensus statements and management algorithms for hepatitis C virus infection.亚太肝脏研究学会丙型肝炎病毒感染共识声明及管理算法
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
4
New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.《亚太地区丙型肝炎新指南:亚太肝脏研究学会关于丙型肝炎病毒感染诊断、管理和治疗的共识声明》
J Gastroenterol Hepatol. 2007 May;22(5):607-10. doi: 10.1111/j.1440-1746.2007.04969.x.
5
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.亚太肝病学会肝癌共识建议。
Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.
6
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.亚太肝脏研究协会关于丙型肝炎病毒感染诊断、管理和治疗的共识声明
J Gastroenterol Hepatol. 2007 May;22(5):615-33. doi: 10.1111/j.1440-1746.2007.04883.x.
7
[Guidelines for the prevention and treatment of hepatitis C (2019 version)].丙型肝炎防治指南(2019年版)
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):962-979. doi: 10.3760/cma.j.issn.1007-3418.2019.12.008.
8
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).急性慢性肝衰竭:亚太肝病学会(APASL)的共识建议。
Hepatol Int. 2009 Mar;3(1):269-82. doi: 10.1007/s12072-008-9106-x. Epub 2008 Nov 20.
9
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.《亚太地区慢性乙型肝炎管理共识声明:2005年更新版》
Liver Int. 2005 Jun;25(3):472-89. doi: 10.1111/j.1478-3231.2005.01134.x.
10
Diagnosis, Management And Prevention Of Hepatitis C In Pakistan 2017.2017年巴基斯坦丙型肝炎的诊断、管理与预防
J Ayub Med Coll Abbottabad. 2016 Oct-Dec;28(4 Suppl 1):S839-S882.

引用本文的文献

1
Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia.来迪派韦/索磷布韦治疗丙型肝炎的长期结果:蒙古的病毒抑制、肝细胞癌和死亡率
Viruses. 2025 May 22;17(6):743. doi: 10.3390/v17060743.
2
CXCL10, SCGN, and H2BC5 as Potential Key Genes Regulated by HCV Infection.CXCL10、SCGN和H2BC5作为受丙型肝炎病毒感染调控的潜在关键基因。
Genes (Basel). 2024 Nov 22;15(12):1502. doi: 10.3390/genes15121502.
3
Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years.韩国慢性丙型肝炎患者接受索非布韦为基础的治疗后持续病毒学应答的预后:一项长达 7 年的多中心前瞻性观察研究数据。
Medicina (Kaunas). 2024 Jul 14;60(7):1132. doi: 10.3390/medicina60071132.
4
Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.在台湾和全球范围内,通过注射吸毒者消除丙型肝炎病毒:挑战与机遇。
Kaohsiung J Med Sci. 2024 Feb;40(2):112-118. doi: 10.1002/kjm2.12788. Epub 2023 Nov 27.
5
Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare.慢性丙型肝炎:急性加重和丙氨酸氨基转移酶 flares。
Viruses. 2023 Jan 8;15(1):183. doi: 10.3390/v15010183.
6
Highly Specific and Rapid Detection of Hepatitis C Virus Using RT-LAMP-Coupled CRISPR-Cas12 Assay.使用逆转录环介导等温扩增(RT-LAMP)耦合CRISPR-Cas12检测法对丙型肝炎病毒进行高特异性快速检测
Diagnostics (Basel). 2022 Jun 23;12(7):1524. doi: 10.3390/diagnostics12071524.
7
Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China.中国广东 HIV/HCV 共感染患者中丙型肝炎病毒的传播网络。
Virol J. 2022 Jul 14;19(1):117. doi: 10.1186/s12985-022-01849-4.
8
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment.韩国某三级医疗机构丙型肝炎病毒关怀链:检测、与治疗关联的现状和变化。
Gut Liver. 2022 Nov 15;16(6):964-975. doi: 10.5009/gnl210416. Epub 2022 Mar 31.
9
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.监狱中丙型肝炎病毒微消除的简化泛基因型直接作用抗病毒治疗方案的现场治疗外展。
World J Gastroenterol. 2022 Jan 14;28(2):263-274. doi: 10.3748/wjg.v28.i2.263.
10
Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting.在社区环境中使用FIB4指数评估肝纤维化
Diagnostics (Basel). 2021 Nov 29;11(12):2236. doi: 10.3390/diagnostics11122236.

本文引用的文献

1
New treatments for HCV: Perspective from Asia.丙型肝炎病毒的新疗法:来自亚洲的视角。
Clin Liver Dis (Hoboken). 2015 Mar 4;5(1):17-21. doi: 10.1002/cld.442. eCollection 2015 Jan.
2
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.治疗结束后24周的持续病毒学应答是预测在现实世界中接受HCV NS3/4A蛋白酶抑制剂联合聚乙二醇干扰素和利巴韦林治疗的丙型肝炎病毒感染患者治疗结局的更好指标。
Int J Med Sci. 2016 Apr 10;13(4):310-5. doi: 10.7150/ijms.14953. eCollection 2016.
3
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.肝硬化患者清除丙型肝炎病毒感染的效果因门静脉高压阶段而异。
Gastroenterology. 2016 Jul;151(1):130-139.e2. doi: 10.1053/j.gastro.2016.03.036. Epub 2016 Apr 1.
4
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.丙型肝炎病毒感染退伍军人持续病毒学应答后发生肝细胞癌的风险
Hepatology. 2016 Jul;64(1):130-7. doi: 10.1002/hep.28535. Epub 2016 Apr 19.
5
Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.丙型肝炎病毒相关性混合性冷球蛋白血症患者对不含干扰素治疗方案的病毒学和临床反应:一项前瞻性试点研究的初步结果
Curr Drug Targets. 2017;18(7):772-785. doi: 10.2174/1389450117666160208145432.
6
National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014.台湾地区2001 - 2014年HIV感染者急性丙型肝炎的全国趋势及特征:一项匹配病例对照研究
PLoS One. 2015 Oct 6;10(10):e0139687. doi: 10.1371/journal.pone.0139687. eCollection 2015.
7
Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report.奥比他韦/帕利瑞韦/利托那韦、达沙布韦和利巴韦林成功治疗丙型肝炎病毒相关冷球蛋白血症:一例报告
J Clin Virol. 2015 Nov;72:66-8. doi: 10.1016/j.jcv.2015.09.003. Epub 2015 Sep 16.
8
APASL consensus statements and management algorithms for hepatitis C virus infection.亚太肝脏研究学会丙型肝炎病毒感染共识声明及管理算法
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
9
Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China.2006年至2012年期间中国浙江省无偿献血者中输血传播感染因子的血清流行率。
Blood Transfus. 2015 Jul;13(3):401-10. doi: 10.2450/2015.0271-14. Epub 2015 Jun 9.
10
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.在无基线NS5A基因多态性的丙型肝炎病毒1b型老年肝硬化患者中,达卡他韦联合阿舒瑞韦治疗可实现高持续病毒学应答
Adv Ther. 2015 Jul;32(7):637-49. doi: 10.1007/s12325-015-0221-5. Epub 2015 Jul 9.